PRESS RELEASE

For immediate release - Marseille (France), February 18th, 2019

C4Diagnostics speed up the Antimicrobial Susceptibility Testing (AST) program with BPI support

C4Diagnostics receives 320K€ from the French Banque Publique d'Investissement (BPI) to support its innovative development program for rapid antimicrobial susceptibility tests (AST)

The amount received from BPI will allow C4Diagnostics to speed up its development program for an automated AST platform based on its proprietary technology. This funding is received while C4Diagnostics is preparing the launch of its first product, C4Legio™, for the diagnosis of Legionnaires’ disease.

The microbial susceptibility testing allows to assess a bacterium strain susceptibility to an antibiotics panel. It’s used to define the right treatment to a bacterial infection for each specific patient. AST is a key test to fight antibiotics resistance – today a major public health issue. In order to fight this resistance issue, targeted treatments and the reduction of empirical treatment are now necessary.

The solution developed by C4Diagnostics is designed for reducing time to results by 3 to 5 time compared to currently used methods. That allows faster targeted patient management and better outcomes.

C4Diagnostics CEO, Younes Lazrak quote « our objective is to have a major impact on patient health and public health concerns. BPI support to our key program, rapid AST, is an important step forward in our journey. ».
ABOUT…

About antibiotic resistance

According to a recent estimate from the European Center for Disease Prevention and Control (ECDC), resistant bacterial infections affect more than 120,000 people a year in France, leading to more than 5,500 deaths.
In Europe, 33,000 people die every year from antibiotic-resistant infections. The burden of these infections is comparable to that of influenza, tuberculosis and HIV/AIDS combined.
In the United States, the Center for Disease Control (CDC) has estimated the annual cost of antimicrobial resistance and misuse of antibiotics to US $55 billion per year for the US economy.

About C4Diagnostics

Based in Marseille, C4Diagnostics designs, develops and markets innovative in Vitro Diagnostic tests in the field of infectious diseases. Winner of numerous awards, C4Diagnostics relies on breakthrough technology, making pathogenic microorganisms quickly visible by using their own metabolism. The ambition of C4Diagnostics is to become one of the major players in infectious diseases field by providing the right information to doctors and patients in a more sensitive and faster way.
C4Diagnostics thus addresses major public health issues such as infection control and antimicrobial resistance control.

C4Diagnostics has been ISO 13485 certified since January 2019.